By JESSICA DaMASSA, WTF HEALTH
You may know the term “digital therapeutics,” but how about the specialized category of “digital neuro-therapeutics”? MindMaze, which has developed a platform approach to creating prescription digital therapeutics for neurological diseases like stroke, Alzheimer’s, and Parkinson’s has just landed $105 million in fresh funding from Concord Health Partners to further advance development of this unique category of pDTx’s.
CEO Tej Tadi, CFO Kevin Gallagher, and Chief Medical Director John Krakauer get us smart on the neuroscience behind MindMaze, their device-plus-gaming interventions, and how they are gaining reimbursement for their brain health and recovery therapies. Each therapeutic is a bit different – MindPod Dolphin, for example, helps patients rehab upper limb motor skills by way of a dolphin-themed gaming experience that incorporates sensors and an anti-gravity vest. The team says there are 10 clinical trials underway across seven indications, with the goal to bring at least three new prescription digital therapeutics to market by next year.
How will this new funding – and a partnership with the American Hospital Association – aid US market expansion for Swiss-based MindMaze? We explore the company’s growth plans, talk about market readiness for digital therapeutics, and even find out the backstory behind how Leonardo DiCaprio ended up on their cap table.